Having been with Pfizer since 2004, Dr. Diane D Wang is currently an executive director at Clinical Pharmacology, Pfizer, Inc.  From 2001 to 2004, she spent more than 3 years at Immunex and Amgen focusing on the development of biotherapeutic agents.  Prior to joining the industry, Dr. Wang was a senior clinical pharmacology reviewer (1993-1999) and pharmacometrics reviewer (1999-2001) at the Office of Clinical Pharmacology, the Food and Drug Administration.  Dr. Wang’s research interest is focused on developing methodology for model validation, applying modeling and simulation in drug development for dose selection, study design, making go/no go decisions, developing general guidance for dosing strategy of biotherapeutic agents, developing an East Asian strategy for an accelerated/more efficient drug development and registration in East Asian countries, and most recently oncology dose optimization.   

王丹博士自 2004 年加入辉瑞公司，目前担任辉瑞临床药理执行总监。在2001 年至 2004 年，王博士任职于 Immunex 和 Amgen ，专注于生物类药物研发。在此之前，王博士曾担任美国食品药品监督管理局临床药理学办公室的高级临床药理审评员（1993-1999）和高级定量药理审评员（1999-2001）。王博士的研究方向集中在模型验证的方法学开发、在药物研发中应用建模和模拟进行剂量选择、试验设计、做出研发决策、制定生物类药物剂量策略指南、制定东亚策略用于在东亚国家更加快速/有效的药物研发和注册，以及最近的肿瘤剂量优化。